Back to results
US 2024/0254241 A1Published application
Antibodies targeting egfr and cd3 and uses thereof
AssigneeJanux Therapeutics, Inc.
InventorsDavid CAMPBELL, Thomas R. DIRAIMONDO, Ramesh BHATT
Life of this patent
Estimating the term…
Abstract
Provided herein are antibodies that selectively bind to EGFR and CD3, pharmaceutical compositions thereof, as well as methods of producing such antibodies.
Claims143
An isolated polypeptide complex according to the following formula:
- wherein
- A comprises a single chain variable fragment (scFv) that binds to CD3;
- B comprises an antigen binding fragment (Fab) or Fab′ that binds to EGFR wherein the Fab or Fab′ comprises a Fab light chain polypeptide comprising a Fab light chain variable domain and a Fab heavy chain polypeptide comprising a Fab heavy chain variable domain comprising complementarity determining region (CDRs):
- HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, the HC-CDR2, and the HC-CDR3 of the Fab heavy chain variable domain comprise HC-CDR1:
- SEQ ID NO:
- 18, HC-CDR2:
- SEQ ID NO:
- 19, and HC-CDR3:
- SEQ ID NO:
- 20, and wherein the CDRs comprise from 0-2 amino acid modifications in at least one of the HC-CDR1, HC-CDR2, or HC-CDR3;
- and
- L comprises a linker that connects A to B.
9 more elements
An isolated polypeptide complex according to the following formula:
- wherein
- A comprises a single chain variable fragment (scFv) that binds to CD3;
- D comprises an antigen binding fragment (Fab) or Fab′ that binds to EGFR;
- and
- L comprises a linker that connects the C-terminus of A to an N-terminus of D.
2 more elements
Dependencies are inferred from the claim text.